Acepodia develops first-in-class cell therapies utilizing Antibody-Cell Conjugation (ACC) technology to enhance the potency and specificity of immune cells against cancer. The company addresses the limitations of traditional cancer treatments by providing targeted therapies that do not require genetic engineering, improving safety and efficacy across various tumor types.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DMFounders
Product
Problem
Current cancer treatments face limitations in effectively targeting and eradicating tumors, particularly solid tumors and hematological malignancies, while also minimizing off-target effects and the need for genetic engineering. Existing cell therapies often struggle with immunosuppression within the tumor microenvironment and the logistical challenges of personalized manufacturing.
Solution
Acepodia is developing off-the-shelf cell therapies using its Antibody-Cell Conjugation (ACC) technology to enhance the specificity and potency of immune cells against cancer. The ACC platform employs a "plug and play" approach, conjugating tumor-targeting antibodies to immune cells like gamma delta (γδ)2 T cells and oNK cells without genetic modification. This approach enhances the ability of immune cells to recognize and engage tumors by unlocking multiple receptor signaling pathways. By combining ACC with allogeneic γδ2 T cells and oNK cells, Acepodia aims to create broadly accessible, scalable cell therapies that overcome tumor defenses and reduce the risk of graft-versus-host disease or cytokine storm syndrome.
Target Audience
Acepodia's primary target audience includes patients with solid tumors and hematological malignancies, as well as clinicians and researchers seeking more effective and accessible cell therapies.
Features
- Antibody-Cell Conjugation (ACC) technology that links tumor-targeting antibodies to immune cells using click chemistry
- Utilizes both gamma delta (γδ)2 T cells and off-the-shelf NK (oNK) cells as the chassis for ACC technology
- ACC-γδ2 T cell therapies that harness the innate and adaptive immune properties of γδ2 T cells
- AD2C (Antibody-Dual-Drugs Conjugation) platform for site-specific conjugation of multiple linker-payloads to antibodies
- Streamlined manufacturing process with cryopreservation for off-the-shelf availability
- Proprietary allogeneic γδ2 T cell production for a consistent and scalable source of cells
- Lead clinical candidates include ACE1831 (CD20-targeting ACC-γδ2 T cell therapy) and ACE2016 (EGFR-targeting ACC-γδ2 T cell therapy)